Vaxcyte Doses First Patient in Phase 1 Trial for Group A Strep Vaccine

On June 2, Vaxcyte (NASDAQ:PCVX) dosed its first participant in a Phase 1 clinical trial of an experimental vaccine against Group A Streptococcus. The company is developing the world's first-in-human candidate to address this disease for which no approved vaccine currently exists.

By Abdul Rahman Mon, June 22, 2026 at 5:14 PM GMT+3 2 min read · Yahoo Finance · June 22, 2026, 14:14 UTC

Vaxcyte Doses First Patient in Phase 1 Trial for Group A Strep Vaccine

Tickers: $PCVX

Topics: biotech clinical trials Group A Strep vaccine development

Read the full article at Yahoo Finance

More Health news

Data Suggests United States May Lose Measles Elimination Status The Verge · November 11, 2026, 19:48 UTC
Rising U.S. Measles Outbreaks Pose Significant Economic Burden CNBC · November 11, 2026, 12:00 UTC
FDA Issues Not Approvable Letter for NovoCure's Optune Mya Motley Fool · November 10, 2026, 18:50 UTC
Immunovant Reports Q2 2026 Financial Results and IMVT-1402 Clinical Data Motley Fool · November 10, 2026, 01:43 UTC
Royalty Pharma Poised to Benefit from Revolution Medicines' FDA-Approved Pancreatic Cancer Drug Motley Fool · November 8, 2026, 15:15 UTC
Acumen Pharmaceuticals Expects Phase II Alzheimer's Trial Results in November 2026 Motley Fool · November 5, 2026, 01:48 UTC
Moderna and Merck Face Manufacturing Challenges for Promising Personalized Cancer Vaccine Motley Fool · November 3, 2026, 20:52 UTC
Amgen's Imdelltra Shows Significant Efficacy in Advanced Lung Cancer Treatment Motley Fool · November 2, 2026, 17:25 UTC
American Association for Physician Leadership Releases New Book on Systems Thinking and Strategic Change PR Newswire · October 30, 2026, 12:51 UTC
Pennsylvania Reports Nearly 1,400 Measles Cases and Five Deaths Seeking Alpha · October 29, 2026, 16:18 UTC